COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR ADVANCED MELANOMA TREATMENT IN PORTUGAL

Author(s)

Silva Miguel L1, Vargas Lopes F2, Pinheiro B1, Wang J3, Xu R3, Pellissier J3, Laires PA2
1Research Centre on the Portuguese Economy –ISEG/ULisboa, Lisboa, Portugal, 2Merck Sharp & Dohme, Oeiras, Portugal, 3Merck & Co., Inc., North Wales, PA, USA

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PCN118

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Oncology

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×